KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Cash from Financing Activities (2016 - 2025)

Resmed (RMD) has disclosed Cash from Financing Activities for 17 consecutive years, with -$258.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 75.11% year-over-year to -$258.3 million, compared with a TTM value of -$796.6 million through Dec 2025, up 22.47%, and an annual FY2025 reading of -$606.3 million, up 45.84% over the prior year.
  • Cash from Financing Activities was -$258.3 million for Q4 2025 at Resmed, down from -$230.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $932.9 million in Q4 2022 and bottomed at -$393.3 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is -$109.6 million, with a median of -$154.8 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 961.99% in 2021, then soared 527.99% in 2022.
  • Year by year, Cash from Financing Activities stood at -$218.0 million in 2021, then skyrocketed by 527.99% to $932.9 million in 2022, then plummeted by 125.61% to -$239.0 million in 2023, then soared by 38.26% to -$147.5 million in 2024, then tumbled by 75.11% to -$258.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RMD at -$258.3 million in Q4 2025, -$230.3 million in Q3 2025, and -$163.9 million in Q2 2025.